Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

St. Francis predicts X-Stop launch in mid-2005

This article was originally published in The Gray Sheet

Executive Summary

FDA-requested information to support approval for firm's X-Stop non-fusion lumbar device is "reasonable" and "readily available," President & CEO Kevin Sidow states. St. Francis will submit the requested data quickly, he says. In September, FDA's Orthopaedic & Rehabilitation Devices Panel voted 5-3 against approval of the device, which is meant to treat lumbar spinal stenosis, due to a lack of radiographic data proving reduction of stenosis-induced pressure on spinal nerve roots (1"The Gray Sheet" Sept. 6, 2004, p. 7). Sidow believes X-Stop is on track for a mid-2005 release in the U.S. Currently, the device is approved in Europe and Japan...

You may also be interested in...



FDA Panel Doubts Lumbar Fusion Alternative’s Imaging Data

St. Francis Medical should collect more detailed radiographic data of its X-Stop non-fusion lumbar device to prove reduction of stenosis-induced pressure on spinal nerve roots, FDA panelists urged Aug. 31

EWG Study Suggests More Than One In 10 Talc-Based Cosmetics Contain Asbestos

The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.

Atlas Biomed Unlocking Japan’s OTC Market With Direct-To-Consumer DNA And Microbiome Tests

Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus. 

UsernamePublicRestriction

Register

OM002075

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel